Navigation Links
WaferGen Announces Delay in Reporting of Second Quarter 2011 Results
Date:8/23/2011

FREMONT, Calif., Aug. 23, 2011 /PRNewswire/ -- WaferGen Biosystems, Inc. (OTCBB:WGBS), a leading developer of state-of-the-art genomic analysis systems, announced today that it intends to file its Quarterly Report on Form 10-Q for the period ended June 30, 2011 within two weeks.  The company had previously filed a Form 12b-25 with the Securities and Exchange Commission relating to its Form 10-Q filing.  

In order to complete its financial statements and other information contained in the Quarterly Report on Form 10-Q, the company needs additional time to finalize the valuation amounts and related accounting treatment of convertible preferred stock, convertible notes and warrants issued on May 27, 2011 in the company's $30.6 million private placement financing.  

About WaferGen Biosystems, Inc. 

WaferGen Biosystems, Inc. develops, manufactures and sells state-of-the-art systems for genomic analysis for the life science and pharmaceutical industries to advance next generation sequencing and ultimately personalized medicine.  WaferGen offers the breakthrough SmartChip Real-Time PCR System, a next-generation Real-Time PCR system for discovery and validation of gene expression patterns (biomarkers) on a single platform. For additional information, please see http://www.wafergen.com.

Forward Looking Statements

This press release contains certain "forward-looking statements" relating to the expected filing date of the company's Form 10-Q for the second quarter of 2011.  Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company.  Actual results may differ materially from the expectations contained in the forward-looking statements.   More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2010 and the company's most recent Quarterly Report on Form 10-Q for the period ended March 31, 2011.  Security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov.  The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

WaferGen Contacts
510-651-4450

Don Huffman, CFO
don.huffman@wafergen.com

Media:  Joyce Strand
joyce.strand@wafergen.com

Investors:  Tim Ryan
tryan@shorehamgroupllc.com
212-242-7777


'/>"/>
SOURCE WaferGen Biosystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen Announces Second Quarter 2008 Financial Results
2. WaferGen to Present at the Seventh Annual BIO Investor Forum
3. NIH Awards Approximately $3M Grant for Research Involving WaferGens SmartChip(TM) Real-Time PCR System at the University of Pittsburgh
4. WaferGen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
5. WaferGen Announces Third Quarter 2008 Financial Results
6. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
7. Data on WaferGens SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference
8. Data on WaferGens SmartChip(TM) System Presented at 16th International Molecular Medicine Tri-Conference
9. WaferGen to Present Data on SmartChip(TM) Real-Time PCR System at Cambridge Healthtech Institutes Quantitative PCR Conference
10. WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research
11. WaferGen Announces Signing of Private Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... ... A recent survey conducted by the Weed Science Society of America (WSSA) ranks ... of broadleaf crops, fruits and vegetables, while common lambsquarters ranks as the weed most ... the 2016 survey, the second conducted by WSSA. A 2015 baseline survey explored ...
(Date:5/23/2017)... ... , ... Vortex Biosciences , provider of circulating tumor cell (CTC) capture ... using Vortex microfluidic technology ” in Nature Precision Oncology on May 8th. The ... and Dr. Matthew Rettig at the University of California, Los Angeles. The publication describes ...
(Date:5/23/2017)... ... 23, 2017 , ... Customers often prefer PLC and ... again. METTLER TOLEDO has released two new videos that show how they have ... the ACT350 into Siemens and Allen Bradley PLCs is easy and fast. ...
(Date:5/21/2017)... Diego, CA (PRWEB) , ... May 20, 2017 ... ... support tool that helps avoid the lengthy trial and error process by finding ... patients. It can also strengthen the doctor-patient relationship through a personalized approach ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
Breaking Biology News(10 mins):